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Genetic variation in fatty acid desaturases (FADS) has previously been linked to long-
chain polyunsaturated fatty acids (PUFAs) in adipose tissue and cardiovascular risk. The
goal of our study was to test associations between six common FADS polymorphisms
(rs174556, rs3834458, rs174570, rs2524299, rs174589, rs174627), intermediate cardiovas-
cular risk factors, and non-fatal myocardial infarction (MI) in a matched population based
case–control study of Costa Rican adults (n = 1756). Generalized linearmodels andmultiple
conditional logistic regression models were used to assess the associations of interest.
Analyses involving intermediate cardiovascular risk factors and MI were also conducted
in two replication cohorts, The Nurses’ Health Study (n = 1200) and The Health Profes-
sionals Follow-Up Study (n = 1295). In the Costa Rica Study, genetic variation in the FADS
cluster was associated with a robust linear decrease in adipose gamma-linolenic, arachi-
donic, and eicosapentaenoic fatty acids, and signiﬁcant or borderline signiﬁcant increases
in the eicosadienoic, eicosatrienoic, and dihomo-gamma-linolenic fatty acids. However, the
associations with adipose tissue fatty acids did not translate into changes in inﬂammatory
biomarkers, blood lipids, or the risk of MI in the discovery or the replication cohorts. In con-
clusion, fatty acid desaturase polymorphisms impact long-chain PUFA biosynthesis, but
their overall effect on cardiovascular health likely involves multiple pathways and merits
further investigation.
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INTRODUCTION
Long-chain omega-3 polyunsaturated fatty acids (PUFAs),
obtained either through dietary intake or synthesized endoge-
nously from alpha-linolenic acid (ALA), have long been known
to be protective against heart disease, diabetes, and other chronic
outcomes (Harris, 2010). Previous studies showed that in popula-
tions with low intake of marine fatty acids, dietary intake of ALA
also confers cardioprotective beneﬁts, either by itself or through
conversion to long-chain PUFAs (Baylin et al., 2003).
The delta5- and delta6-desaturases, encoded by FADS1 and
FADS2 genes respectively, play a critical role in the conversion
pathway and could have implications for chronic disease risk,
especially in the context of a long-chain PUFA deﬁcient diet (Lat-
tka et al., 2009; Figure 1). Several studies, including a recent
meta-analysis of genome-wide association (GWA) scans, linked
polymorphisms in the FADS gene cluster to PUFA concentrations
in serum phospholipids and erythrocyte cell membranes in sev-
eral populations, including Caucasians, East Asians, and African
Americans (Malerba et al., 2008; Martinelli et al., 2008; Rzehak
et al., 2009; Tanaka et al., 2009; Kwak et al., 2011; Lemaitre et al.,
2011; Mathias et al., 2011). Additionally, a number of studies have
reported signiﬁcant associations between FADS genotypes and
the risk of coronary artery disease (Martinelli et al., 2008; Kwak
et al., 2011). A previous analysis of our data from the Costa Rican
population examined the effect of a common single nucleotide
polymorphism (SNP) in the FADS2 promoter region on the risk of
non-fatal myocardial infarction (MI; Baylin et al., 2007). Although
a consistent decrease in adipose and plasma PUFA concentrations
was observed with an increase in number of copies of the minor
allele, the association with MI was not signiﬁcant (Baylin et al.,
2007).
The mechanisms by which genetic variation in desaturases
impacts cardiovascular health are unclear and likely to involve
multiple pathways. A recent study has linked the number of risk
alleles in the FADS cluster to high-sensitivity C-reactive pro-
tein (hsCRP) concentrations and prevalence of coronary artery
disease, suggesting inﬂammation as amechanism of interest (Mar-
tinelli et al., 2008). Another potential pathway supported by
extensive evidence from genome-wide studies links desaturase
polymorphisms to changes in serum cholesterol and triglycerides
(Aulchenko et al., 2009; Kathiresan et al., 2009; Sabatti et al., 2009;
Lettre et al., 2011).
While most published studies have considered FADS gene vari-
ants and cardiovascular outcomes individually, the complex nature
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FIGURE 1 | Biosynthetic pathway of polyunsaturated fatty acids.
of biological mechanisms underlying the association between
desaturases and cardiovascular risk warrants a more compre-
hensive approach. The objective of this study is to evaluate the
association between genetic variation in the FADS cluster, adipose
tissue fatty acids, serum lipids, and inﬂammatory biomarkers, and
the risk of MI in a Costa Rican population. By considering inter-
mediate outcomes as well as the endpoint of MI, this study aims
to provide novel mechanistic insights into the relation between
desaturases, dietary fatty acids, and cardiovascular disease.
MATERIALS AND METHODS
STUDY POPULATION
The population of theCosta Rica Study,described in detail in prior
publications, included 4,548 unrelated Hispanics who resided in
the Central Valley of Costa Rica between 1994 and 2004 (Baylin
and Campos, 2004; Kabagambe et al., 2007). Cases of ﬁrst non-
fatal acute MI were ascertained by two independent cardiologists
in the participating hospitals and deemed eligible if they met
the World Health Organization criteria, survived hospitalization,
were under 75 years of age on the day of their ﬁrst MI, and able
to answer the questionnaire (Tunstallpedoe et al., 1994). Eligible
cases were matched by 5-year age group, sex, and area of resi-
dence to population controls. Participation was 98% for cases and
88% for controls. The study population is appropriate for inves-
tigating genetic markers of disease due to its origin in a small
number of founders and low rates of migration (Baylin et al.,
2007).
Theoriginal sample sizewas 2,274 cases and2,274 controls. Par-
ticipants missing information on outcomes, exposure, or covari-
ates were excluded from the analysis. Excluded participants did not
signiﬁcantly differ from those who remained in the analyses on key
demographic, genetic, and dietary variables. Data were missing
due to lost laboratory samples as well as non-differential response
patterns with respect to the exposure, outcome, or covariates.
All participants provided written informed consent. The study
was approved by the Human Subjects Committee of the Harvard
School of Public Health and the University of Costa Rica.
The replication study populations consisted of the Nurses
Health Study (NHS) and Health Professionals Follow-Up Study
(HPFS) participants. The NHS enrolled 121,701 female nurses
aged 30–55 who returned a mailed questionnaire in 1976 regard-
ing lifestyle and medical history. The HPFS enrolled 51,529 males
aged 40–75 who returned a similar questionnaire in 1986. Par-
ticipants of both cohorts have received follow-up questionnaires
biennially to record newly diagnosed illnesses. Detailed descrip-
tions of the study cohorts have been published previously (Colditz
et al., 1997).
In both replication cohorts, nested case–control studies were
designed using incident coronary heart disease (CHD), with non-
fatal MI and fatal CHD as the outcome. Diagnosis of MI was
conﬁrmed on the basis of the criteria of the World Health Organi-
zation (Tunstallpedoe et al., 1994). Fatal CHDwas conﬁrmedby an
examination of hospital or autopsy records. Among participants
who provided blood samples and who were free of diagnosed car-
diovascular disease or cancer at blood draw, 474 women and 454
men with incident CHD between blood draw and June of 2004
were identiﬁed. Using risk-set sampling (Prentice and Breslow,
1978), controls were selected randomly and matched in a 1:2 ratio
on age, smoking, and month of blood return, yielding ﬁnal sample
sizes of 1200 for NHS and 1295 for HPFS.
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BIOCHEMICAL MEASUREMENTS
In the Costa Rica Study, exposures were ascertained via adi-
pose tissue biomarkers for the following fatty acids: 18:3n−3
(ALA), 18:2n−6 (LA), 18:3n−6 (gamma-linolenic acid, GLA),
20:3n−3 (eicosatrienoic acid, ETA), 20:2n−6 (eicosadienoic acid,
EDA), 20:3n−6 (dihomo-gamma-linolenic acid, DGA), 20:4n−6
(arachidonic acid, AA), 20:5n−3 (eicosapentaenoic acid, EPA),
and 22:6n−3 (docosahexaenoic acid, DHA). Advantages of using
adipose tissue biomarkers to characterize long-term nutritional
intake include slow turnover, absence of recall bias, and lack
of response to conditions of acute disease (Baylin et al., 2002).
However, adipose tissue concentrations of AA are poorly corre-
lated with dietary intake due to high metabolic regulation (Baylin
et al., 2002). Therefore, we used adipose tissue AA as a meta-
bolic marker representing the endogenous component explained
by genetic variation, adjusted for dietary intake as measured by the
previously validated food frequency questionnaire (Kabagambe
et al., 2001). Subcutaneous adipose biopsies, collected following an
overnight fast, were performed using a modiﬁcation of the Beynen
and Katan method with a plastic syringe instead of a vacutainer
(Beynen and Katan, 1985). Fatty acids from adipose tissue were
quantiﬁed by gas–liquid chromatography (Baylin et al., 2002).
Peak retention times and area percentages of total fatty acids were
analyzed with the ChemStation A.08.03 software (Agilent Tech-
nologies; Truong et al., 2009). Average coefﬁcients of variation for
12 blind duplicates were 3.6% for LA, 6.4% for ALA, 21.7% for
GLA, 7.3% for EDA, 7.6% for DGA, 43.6% for ETA, 11.0% for
AA, 20.3% for EPA, and 14.8% for DHA. Samples were stored
at −80˚C and run within a year of collection. Control samples
were run from 2001 to 2003 and no evidence of analyte instability
was found.
Biomarker analyses of inﬂammation and serum lipids were
restricted to control subjects to preclude reverse causation. Blood
samples were collected during the home visits; the tubes were cen-
trifuged within 6 h at 2,500 rpm for 20min to separate plasma.
Plasma triglycerides, low density lipoprotein (LDL), high den-
sity lipoprotein (HDL), and total cholesterol were assayed with
enzymatic reagents (Boehringer-Mannheim) and standardized
according to the program speciﬁed by theCenters forDiseaseCon-
trol and the National Heart, Lung, and Blood Institute (Williams
et al., 2007). To measure inﬂammation, the study used hsCRP
and vascular cellular adhesion molecule-1 (VCAM-1), two plasma
biomarkers that have been extensively validated and linked to car-
diovascular risk in large-scale prospective studies (Ridker et al.,
2000; Blankenberg et al., 2001). Concentrations of hsCRP were
measured using immunoturbidimetry onRocheModular P chem-
istry autoanalyzer (Hoffman La Roche, average coefﬁcient of vari-
ation= 1.42%). The Quantikine Human sVCAM-1 assay (R&D
Systems, kit lot # 258820) was used to measure sVCAM-1 (average
coefﬁcient of variation= 9.58%).
Between 1989 and 1990, a blood sample was requested from
all active participants in NHS and collected from 32,826 women.
Similarly, blood samples were requested between 1993 and 1995
and obtained from 18,225 HPFS participants. Plasma lipids and
inﬂammatory markers were assessed using standard methods with
reagents from Roche Diagnostics (Indianapolis, IN, USA) and
Bayer Diagnostics (New York, NY, USA; Pai et al., 2002).
SNP SELECTION
Seven SNPs located on the FADS gene cluster were selected for
analysis based on previously published evidence of their role in
fatty acid metabolism, linkage disequilibrium patterns, and avail-
ability in the Costa Rican population: rs174556 (C/T), rs3834458
(T/deletion), rs174570 (C/T), rs2524299 (A/T), rs174589 (C/G),
rs174611 (T/C), rs174627 (C/T; Baylin et al., 2002; Malerba et al.,
2008; Tanaka et al., 2009).
GENOTYPING
A DNA stock sample of ∼200mg was collected from all study
participants and stored at −80˚C in Costa Rica. This sample was
extracted from frozen buffy coats using the Qiagen QIAamp DNA
Blood Kit. Purity was determined by the ratio of absorbance at
260–280 (A260/A280) to be between 1.7 and 1.9 for all samples.
For high-throughput genotyping 15 ng/ml “working solutions”
were prepared and aliquoted into 96-well plates. Genotyping was
performed at the University of Cincinnati using the SNPlex Geno-
typing System (Applied Biosystems). Fragmented genomic DNA
(50 ng)was dried into eachwell of a 384-well plate (∼1 ngDNAper
genotype).After phosphorylation of oligonucleotide ligation assay
(OLA) probes and universal linkers, allele-speciﬁc ligation, and
enzymatic puriﬁcation were performed. Polymerase chain reac-
tion (PCR) utilized universal biotinylated primers, so amplicons
could be captured on streptavidin-coated plates. Single-strand
PCR products were hybridized with a universal set of ﬂuores-
cently dye-labeled mobility modiﬁers, the ZipChute probes that
have a unique sequence corresponding to each SNP. ZipChute
probes were eluted and separated for detection by capillary elec-
trophoresis on ABI PRISM 3130XL DNA Analyzer (Applied
Biosystems). Data were collected, formatted, processed, and ana-
lyzed using the GeneMapper Analysis Software (Version 4.0),
which assigned individual genotypes. Genotyping was attempted
on 4,082 individuals (90% of the total study population); of
those, call rates ranged from 74% (for rs174570) to 93% (for
rs3834458).
Ancestry was estimated using a set of 39 informative markers
selected from published lists of validated SNPs with allele fre-
quencies from Amerindian, European, and West African samples
(Ruiz-Narváez et al., 2010). Based on the set of selected markers,
the expected variance of estimated individual ancestral propor-
tions for any particular set of loci was calculated using a maximum
likelihood approach with a high degree of precision (SE ≈0.15;
Ruiz-Narváez et al., 2010).
For the NHS and the HPFS, genotyping was performed at
Merck Research Laboratories (North Wales, PA, USA). Genotyp-
ingwas doneusing theAffymetrixGenome-WideHuman6.0 array
and the Birdseed calling algorithm (Korn et al., 2008). Ninety-six
percentage of the NHS samples and 98% of the HFPS sam-
ples were successfully genotyped. SNPs that were monomorphic,
had a missing call rate ≥2%, a Hardy–Weinberg equilibrium p
value< 1× 10−4,or aminor allele frequency<0.02were excluded,
leaving a total of 724,881 in HPFS and 721,316 in NHS for analysis
of called genotypes. Imputation of ∼2.5 million SNPs was per-
formedusingMACHsoftware (Version1.0.16)withHapMapCEU
phased II data (Release 22) as the reference panel. Of SNPs used
in the analyses, three (rs174556, rs147570, rs2524299) were on the
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Affymetrix chip,while two (rs174589 and rs174627) were imputed
with r2 values> 0.85.
STATISTICAL ANALYSIS
Data were analyzed using the SAS software package (Version 9.2;
SAS Institute Inc, Cary, NC, USA). To assess the signiﬁcance of
differences in general characteristics and potential confounders,
we used paired t -tests for continuous variables, McNemar’s tests
for categorical variables, and Fisher’s exact test for minor allele fre-
quencies. The ALLELE procedure was used to test for deviations
from Hardy–Weinberg equilibrium among controls. Of all SNPs,
only rs174611 was found to be in violation of the Hardy–Weinberg
equilibrium and removed from all subsequent analyses.
Linear regression models were ﬁt among controls to evalu-
ate the association between each FADS cluster SNP, adipose tis-
sue long-chain PUFAs, and plasma hsCRP, VCAM-1, and serum
lipids. Least square means and 95% conﬁdence intervals were
used to report the relation between the outcomes and FADS
genetic variants. Normal probability plots were constructed, log-
transformations were carried out for non-normally distributed
variables (GLA, hsCRP, and triglycerides), and geometric means
were reported. The intermediate risk factors models were adjusted
for age, sex, and residence area, while the PUFA models were addi-
tionally adjusted for dietary intake of all nine fatty acids as assessed
by the food frequency questionnaire. Adipose tissue PUFAs and
intermediate risk factors were modeled as continuous variables.
The relation between the SNPs and the dichotomous MI out-
come was modeled using conditional logistic regression, adjusted
for age, sex, and residence area. Additionally, models ﬁt to the
Costa Rica Study data were adjusted for ancestry due to evidence
of population stratiﬁcation (Ruiz-Narváez et al., 2010); models
ﬁt to the NHS and the HPFS data were not adjusted for ances-
try as the cohorts were found to be genetically homogeneous.
Least squaremeans of adipose fatty acids, blood lipids, and inﬂam-
matory markers were estimated using PROC GLM, adjusted for
potential confounders listed above. P values from single SNP
analyses were adjusted for multiple comparisons using the false
discovery rate controlling procedure (Benjamini and Hochberg,
1995).
Linear and conditional logistic regression analyseswith individ-
ual SNPs as predictors and inﬂammation markers, blood lipids,
and MI as outcomes as described above were replicated in the
NHS and HPFS. Genotype information at the rs3834458 locus
was not available in the replication cohorts. Because minor allele
frequencies varied considerably between the discovery and repli-
cation cohorts, a meta-analysis was not attempted. All analyses
were adjusted for sex and age.
RESULTS
The general characteristics of the three populations are summa-
rized by case/control status in Table 1. None of the selected SNPs
differed signiﬁcantly in minor allele frequency by disease status.
Cases were more likely to report MI risk factors, speciﬁcally smok-
ing and history of chronic disease. Additionally, cases in the Costa
Rica Study had signiﬁcantly lower adipose tissue concentrations
of ALA and LA. Ancestral admixture proportions did not vary by
Table 1 | General characteristics of the study populations.
Variable Costa Rica Study Nurses’ Health Study Health Professionals
Follow-Up Study
Cases
(n=878)
Controls
(n=878)
Cases
(n=403)
Controls
(n=797)
Cases
(n=435)
Controls
(n=860)
Age, years 58.2±10.9 58.1±11.0 60.2±6.3 59.6±6.5 64.5±8.6 64.2±8.6
% Female 26 26 100 100 0 0
% History of hypertension 39 32 50 27 37 29
% History of hypercholesterolemia 31 29 53 41 49 40
% History of diabetes 23 15 15 6 9 4
% Current smokers 38 21 27 25 10 9
BMI, kg/m2 26.0±4.0 26.5±4.3 26.6±5.4 25.1±4.3 26.0±3.2 25.6±3.3
DIETARY INTAKE OF FATTYACIDS, g
Alpha-linolenic 1.71±0.86 1.61±0.77 – – – –
Linoleic 19.1±9.6 17.9±7.9 – – – –
ADIPOSETISSUE FATTYACIDS, %TOTAL
Alpha-linolenic 0.64±0.21 0.68±0.21 – – – –
Linoleic 15.4±3.7 16.0±3.8 – – – –
MINORALLELE FREQUENCY, %
rs174556 (C/T) 45 45 31 28 30 29
rs3834458 (T/deletion) 48 48 – – – –
rs174570 (C/T) 37 39 13 13 13 14
rs2524299 (A/T) 28 26 12 11 11 13
rs174589 (G/C) 30 29 22 21 20 20
rs174627(C/T) 12 11 18 19 17 17
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Table 2 | Least square means1 (±SE) of selected adipose fatty acids (% of total adipose fatty acids) by genotype among controls in the Costa
Rica Study (n =1032 unless indicated otherwise).
rs174556 (FADS1)
CC CT TT P value2
AA 15.78±0.18 15.93±0.15 15.92±0.21 0.76
GLA (n =983) 0.069±0.002 0.062±0.002 0.054±0.002 <0.0001
ALA 0.64±0.01 0.66±0.01 0.67±0.01 0.04
EDA 0.212±0.003 0.221±0.002 0.228±0.004 0.004
DGA (n =1024) 0.305±0.005 0.321±0.004 0.332±0.006 0.003
ETA 0.0186±0.0006 0.0215±0.0005 0.0240±0.0007 <0.0001
AA (n =1031) 0.54±0.01 0.49±0.01 0.42±0.01 <0.0001
EPA 0.045±0.001 0.044±0.001 0.036±0.002 <0.0001
DHA 0.143±0.003 0.142±0.002 0.137±0.003 0.36
rs3834458 (FADS1/FADS2 INTERGENIC)
TT T− – P value
AA 16.08±0.19 15.78±0.14 15.85±0.20 0.42
GLA (n =983) 0.067±0.002 0.063±0.003 0.057±0.002 0.0003
ALA 0.65±0.01 0.65±0.01 0.66±0.01 0.74
EDA 0.216±0.003 0.218±0.003 0.227±0.004 0.07
DGA (n =1024) 0.308±0.006 0.321±0.004 0.325±0.006 0.08
ETA 0.0190±0.0006 0.0211±0.0005 0.0234±0.0006 <0.0001
AA (n =1031) 0.54±0.01 0.49±0.01 0.43±0.01 <0.0001
EPA 0.045±0.001 0.044±0.001 0.037±0.001 <0.0001
DHA 0.143±0.003 0.142±0.002 0.136±0.003 0.21
rs174570 (FADS2)
CC CT TT P value
AA 15.97±0.16 15.81±0.14 15.87±0.25 0.74
GLA (n =983) 0.068±0.002 0.060±0.001 0.057±0.002 <0.0001
ALA 0.65±0.01 0.66±0.01 0.65±0.01 0.77
EDA 0.212±0.003 0.224±0.003 0.225±0.005 0.003
DGA (n =1024) 0.308±0.005 0.326±0.004 0.318±0.008 0.02
ETA 0.0192±0.0005 0.0220±0.0005 0.0230±0.0008 <0.0001
AA (n =1031) 0.53±0.01 0.48±0.01 0.43±0.01 <0.0001
EPA 0.047±0.001 0.041±0.001 0.037±0.002 <0.0001
DHA 0.145±0.003 0.141±0.002 0.134±0.004 0.07
rs2524299 (FADS1)
AA AT TT P value
AA 15.88±0.14 15.85±0.16 16.04±0.35 0.88
GLA (n =983) 0.066±0.002 0.064±0.002 0.062±0.003 <0.0001
ALA 0.65±0.01 0.66±0.01 0.63±0.02 0.51
EDA 0.217±0.002 0.221±0.003 0.234±0.006 0.04
DGA (n =1024) 0.321±0.004 0.311±0.005 0.331±0.011 0.13
ETA 0.0206±0.0004 0.0215±0.0005 0.0227±0.0011 0.05
AA (n =1031) 0.51±0.01 0.46±0.01 0.44±0.02 <0.0001
EPA 0.044±0.001 0.041±0.001 0.037±0.003 0.004
DHA 0.145±0.002 0.138±0.003 0.130±0.006 0.02
rs174589 (FADS2)
GG CG CC P value
AA 15.80±0.14 15.98±0.16 15.92±0.30 0.67
GLA (n =983) 0.063±0.002 0.062±0.002 0.060±0.003 0.21
ALA 0.64±0.01 0.66±0.01 0.67±0.02 0.08
EDA 0.216±0.003 0.222±0.003 0.228±0.005 0.07
DGA (n =1024) 0.310±0.004 0.322±0.005 0.345±0.009 0.008
ETA 0.0200±0.0004 0.0218±0.0005 0.0235±0.0009 0.0001
AA (n =1031) 0.51±0.01 0.47±0.01 0.46±0.01 <0.0001
(Continued)
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Table 2 | Continued
EPA 0.043±0.001 0.042±0.001 0.039±0.002 0.09
DHA 0.140±0.002 0.140±0.003 0.150±0.005 0.16
rs174627 (FADS2/FADS3 INTERGENIC)
CC CT TT P value
AA 15.91±0.12 15.75±0.22 15.87±0.93 0.78
GLA (n =983) 0.062±0.001 0.061±0.002 0.065±0.009 0.79
ALA 0.65±0.01 0.65±0.01 0.68±0.05 0.88
EDA 0.220±0.002 0.218±0.004 0.204±0.017 0.58
DGA (n =1024) 0.317±0.003 0.319±0.007 0.371±0.028 0.15
ETA 0.0211±0.0004 0.0211±0.0007 0.0205±0.0030 0.98
AA (n =1031) 0.49±0.02 0.47±0.01 0.53±0.04 0.21
EPA 0.043±0.001 0.042±0.002 0.043±0.007 0.95
DHA 0.141±0.002 0.142±0.004 0.145±0.015 0.96
1Models were adjusted for age/sex/residence (by matching), ancestry, and dietary fatty acids.
2Unadjusted for multiple testing.
Table 3 | Least square means1 (±SE) of blood lipids and inflammatory markers by FADS genotype among controls.
rs174556 (FADS1)
CC CT TT P value2
hsCRP, mg/L
Costa Rica Study (n =836) 2.54±0.16 2.01±0.11 2.01±0.15 0.01
NHS (n =797) 1.77±0.10 1.85±0.12 1.50±0.24 0.39
HPFS (n =860) 1.13±0.07 1.00±0.06 0.96±0.16 0.23
VCAM-1, ng/mL
Costa Rica Study (n =838) 737.17±16.31 724.45±13.69 742.18±19.41 0.69
NHS (n =411) 658.29±10.61 650.22±11.06 628.53±21.59 0.45
HPFS (n =508) 1279.12±18.28 1280.45±19.62 1264.07±44.85 0.94
Total cholesterol, mg/dL
Costa Rica Study (n =1026) 211.52±2.49 211.85±2.05 209.38±2.97 0.77
NHS (n =797) 226.82±1.98 226.64±2.24 221.36±4.98 0.58
HPFS (n =860) 203.69±1.73 201.99±1.89 197.03±4.40 0.35
LDL cholesterol, mg/dL
Costa Rica Study (n =951) 131.75±2.22 131.41± 1.81 127.64±2.65 0.41
NHS (n =797) 135.19±1.85 135.38±2.10 130.72±4.66 0.64
HPFS (n =860) 127.15±1.50 125.89±1.64 120.28±3.81 0.38
HDL cholesterol, mg/dL
Costa Rica Study (n =1021) 41.70±0.53 42.51±0.43 41.37±0.63 0.23
NHS (n =797) 60.27±0.83 59.67±0.94 61.34±2.09 0.74
HPFS (n =860) 46.21±0.60 45.72±0.66 46.23±1.53 0.85
Triglycerides, mg/dL
Costa Rica Study (n =1026) 183.62±4.97 183.82±4.11 195.57±6.28 0.17
NHS (n =540) 102.26±3.03 101.09±3.37 90.50±7.22 0.31
HPFS (n =492) 110.05±3.77 120.49±4.54 109.41±9.51 0.16
rs174570 (FADS2)
CC CT TT P value
hsCRP, mg/L
Costa Rica Study (n =836) 2.43±0.14 2.02±0.11 2.04±0.19 0.04
NHS (n =797) 1.81±0.09 1.67±0.15 2.21±0.91 0.54
HPFS (n =860) 1.05±0.05 1.12±0.09 0.60±0.24 0.13
VCAM-1, ng/mL
Costa Rica Study (n =838) 733.25±15.21 721.78±13.25 768.79±23.88 0.2
NHS (n =411) 648.29±8.32 657.52±14.82 707.41±59.58 0.49
HPFS (n =508) 1275.07±14.84 1304.30±25.94 1088.09±81.45 0.04
(Continued)
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Table 3 | Continued
Total cholesterol, mg/dL
Costa Rica Study (n =1026) 209.67±2.31 212.45±2.02 211.01±3.56 0.64
NHS (n =797) 226.89±1.64 225.24±2.97 214.87±10.73 0.50
HPFS (n =860) 203.74±1.44 199.75±2.46 187.25±9.29 0.09
LDL cholesterol, mg/dL
Costa Rica Study (n =951) 131.61±2.05 130.46±1.79 129.22±3.25 0.80
NHS (n =797) 135.23±1.53 134.19±2.78 130.22±10.04 0.85
HPFS (n =860) 127.20±1.24 123.98±2.13 109.54±8.05 0.05
HDL cholesterol, mg/dL
Costa Rica Study (n =1021) 41.71±0.49 42.06±0.43 42.61±0.76 0.58
NHS (n =797) 60.19±0.69 60.05±1.24 57.66±4.50 0.86
HPFS (n =860) 46.45±0.50 45.06±0.86 41.23±3.24 0.12
Triglycerides, mg/dL
Costa Rica Study (n =1026) 178.41±4.47 186.53± 4.11 206.62±7.87 0.002
NHS (n =540) 101.54±2.50 99.23±4.36 93.64±15.69 0.78
HPFS (n =492) 112.35±3.15 120.33±5.89 95.19±39.01 0.37
rs2524299 (FADS2)
AA AT TT P value
hsCRP, mg/L
Costa Rica Study (n =836) 2.20±0.11 2.17±0.13 1.95±0.24 0.53
NHS (n =797) 1.75±0.08 1.89±0.18 1.93±1.07 0.73
HPFS (n =860) 1.06±0.05 1.07±0.10 0.73±0.33 0.51
VCAM-1, ng/mL
Costa Rica Study (n =838) 730.65±12.71 740.39±15.01 701.03±33.64 0.54
NHS (n =411) 653.92±8.21 642.34±15.29 681.19±84.08 0.73
HPFS (n =508) 1280.63±14.55 1276.65±27.90 1186.94±108.41 0.67
Total cholesterol, mg/dL
Costa Rica Study (n =1026) 210.52±1.91 211.91±2.30 213.08±4.93 0.82
NHS (n =797) 225.79±1.61 228.19±3.14 227.26±1340 0.79
HPFS (n =860) 202.07±1.40 205.10±2.59 182.39±9.99 0.08
LDL cholesterol, mg/dL
Costa Rica Study (n = 951) 130.59±1.70 131.59±2.04 126.97±4.48 0.63
NHS (n =797) 134.10±1.50 137.61±2.93 141.59±12.51 0.49
HPFS (n =860) 126.12±1.22 127.61±2.24 101.69±8.64 0.02
HDL cholesterol, mg/dL
Costa Rica Study (n =1021) 41.96±0.41 41.94±0.49 42.74±1.05 0.77
NHS (n =797) 60.51±0.67 58.75±1.31 57.62±5.60 0.44
HPFS (n =860) 46.10±0.49 45.66±0.90 46.39±3.49 0.91
Triglycerides, mg/dL
Costa Rica Study (n =1026) 183.29±3.83 186.45±4.66 209.11±10.92 0.06
NHS (n =540) 100.72±2.44 101.51±4.59 93.21±22.32 0.91
HPFS (n =492) 111.87±3.05 124.82±6.61 78.38±26.46 0.05
rs174589 (FADS2)
GG CG CC P value
hsCRP, mg/L
Costa Rica Study (n =836) 2.26±0.23 1.81±0.11 2.46±0.13 0.01
NHS (n =797) 1.31±0.09 1.85±0.14 1.77±0.34 0.28
HPFS (n =860) 0.84±0.06 0.95±0.07 1.13±0.18 0.06
VCAM-1, ng/mL
Costa Rica Study (n =838) 756.39±27.85 735.17±14.87 725.40±13.08 0.57
NHS (n =411) 628.94±9.28 654.72±12.26 651.70±32.61 0.75
HPFS (n =508) 1276.34±16.16 1270.26±22.63 1282.77±55.93 0.90
(Continued)
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Table 3 | Continued
Total cholesterol, mg/dL
Costa Rica Study (n =1026) 207.66±4.16 212.08±2.25 211.34±1.99 0.63
NHS (n =797) 225.22±7.42 220.30±2.44 229.60±1.79 0.009
HPFS (n =860) 195.14±5.62 200.88±2.23 203.72±1.52 0.24
LDL cholesterol, mg/dL
Costa Rica Study (n =951) 126.31±3.79 130.24±1.98 132.01±1.77 0.36
NHS (n =797) 128.04±6.94 130.41±2.28 137.73±1.67 0.02
HPFS (n =860) 120.75±4.87 124.70±1.94 127.12±1.32 0.31
HDL cholesterol, mg/dL
Costa Rica Study (n =1021) 41.87±0.88 42.22±0.48 41.88±0.42 0.84
NHS (n =797) 65.53±3.12 59.77±1.92 59.99±0.75 0.21
HPFS (n =860) 43.63±1.96 46.72±0.78 45.85±0.53 0.30
Triglycerides, mg/dL
Costa Rica Study (n =1026) 201.76±8.97 186.19±4.57 183.06±3.98 0.09
NHS (n =540) 100.87±2.76 95.79±3.49 103.66±15.33 0.20
HPFS (n =492) 113.02±3.50 113.94±4.95 114.45±12.79 0.99
rs174627 (FADS2/FADS3 INTERGENIC)
CC CT TT P value
hsCRP, mg/L
Costa Rica Study (n =836) 2.25±0.10 1.84±0.14 2.95±0.72 0.12
NHS (n =797) 1.75±0.09 1.88±0.15 1.57±0.40 0.58
HPFS (n =860) 1.09±0.05 0.98±0.08 0.97±0.23 0.45
VCAM-1, ng/mL
Costa Rica Study (n =838) 734.33±10.86 727.08±20.49 685.99±80.80 0.80
NHS (n =411) 660.18±9.12 636.57±12.53 639.80±33.07 0.28
HPFS (n =508) 1286.08±15.42 1245.81±24.13 1360.67±65.90 0.14
Total cholesterol, mg/dL
Costa Rica Study (n =1026) 211.77±1.64 209.06±3.08 210.53±12.92 0.72
NHS (n =797) 227.65±1.75 222.73±2.59 231.10±7.33 0.23
HPFS (n =860) 202.56±1.47 202.24±2.40 201.93±6.09 0.99
LDL cholesterol, mg/dL
Costa Rica Study (n =951) 131.48±1.46 127.79±2.73 129.84±11.62 0.47
NHS (n =797) 135.68±1.64 132.90±2.42 137.24±6.85 0.60
HPFS (n =860) 125.93±1.28 126.81±2.08 124.04±5.28 0.87
HDL cholesterol, mg/dL
Costa Rica Study (n =1021) 41.80±0.35 42.77±0.65 43.96±2.73 0.30
NHS (n =797) 60.10±0.73 59.82±1.09 62.63±3.07 0.69
HPFS (n =860) 46.25±0.51 45.77±0.84 43.34±2.12 0.39
Triglycerides, mg/dL
Costa Rica Study (n =1026) 185.32±6.55 190.18±6.34 178.07±22.41 0.63
NHS (n =540) 102.45±2.66 96.80±3.80 104.69±12.53 0.43
HPFS (n =492) 112.80±3.24 114.44±5.57 138.56±17.60 0.21
1Models ﬁt to the Costa Rican data were adjusted for age/sex/residence (by matching) and ancestry. Models ﬁt to the Nurses’ Health Study and the Health Profes-
sionals Follow-Up Study data were adjusted for sex and age.
2Unadjusted for multiple testing.
case–control status in the discovery cohort and were estimated at
58% European, 38% Amerindian, and 4% West African.
As shown in Table 2, least square means of adipose tissue ALA
and LA did not vary signiﬁcantly by FADS genotype in the Costa
Rica Study. Upon adjustment for multiple testing, variation at the
rs174627 locus was not associated with any of the fatty acid out-
comes. For all the remaining SNPs, the number of variant allele
copies was signiﬁcantly associated with a decrease in adipose AA.
Additionally, variation at all loci except rs174589 and rs174627was
associated with decreased adipose GLA and EPA, while for most
SNPs, adipose EDA, DGA, and ETA increased with the number of
variant allele copies. The direction of association was consistent
across SNPs.
Table 3 shows the least square means of blood lipids and
inﬂammatory biomarkers by FADS genotype.After adjustment for
multiple comparisons, no signiﬁcant associations were observed
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between the FADS cluster SNPs and intermediate cardiovascular
risk factors, with the sole exception of a statistically signiﬁcant
increase in triglycerides across the number of variant copies in
rs174570 in the Costa Rica Study; however, the association was
not replicated in the NHS or the HFPS. Variation in the FADS
genes was not associated with the risk of MI in any of the three
study populations (Table 4).
DISCUSSION
Our ﬁndings show that genetic variation in the FADS cluster
is associated with adipose tissue fatty acids in the Costa Rica
Study. In particular, we demonstrated associations of multiple
desaturase SNPs with decreases in adipose AA, GLA, and EPA
as well as with increases in adipose EDA, ETA, and DGA. Our
results contribute to the body of evidence in support of robust
associations between long-chain PUFAs and FADS cluster poly-
morphisms, including a recentmeta-analysis of GWA studies from
the CHARGE consortium (Lemaitre et al., 2011). Speciﬁcally, in
concordance with our ﬁndings, the strongest signal in the FADS
cluster reported by Tanaka et al. (2009, rs174537) was similarly
associated with a decrease in long-chain PUFA (namely AA and
EPA) concentrations.
The observed associations of desaturase polymorphisms with
adipose fatty acids, however, do not translate into signiﬁcant
changes in serum lipids, inﬂammatory biomarkers, or the risk of
Table 4 |The risk of non-fatal myocardial infarction associated with the
number of copies of the variant allele.
OR1 (95% CI) P value2
rs174556 (FADS1)
Costa Rica Study (n =1756) 1.02 (0.89, 1.16) 0.77
NHS (n =1200) 1.10 (0.91, 1.32) 0.34
HPFS (n =1295) 1.06 (0.88, 1.26) 0.56
rs174570 (FADS2)
Costa Rica Study (n =1756) 0.91 (0.79, 1.05) 0.17
NHS (n =1200) 0.99 (0.76, 1.29) 0.95
HPFS (n =1295) 0.86 (0.67, 1.10) 0.24
rs2524299 (FADS2)
Costa Rica Study (n =1756) 1.09 (0.94, 1.26) 0.27
NHS (n =1200) 1.02 (0.78, 1.33) 0.91
HPFS (n =1295) 0.86 (0.67, 1.12) 0.27
rs174589 (FADS2)
Costa Rica Study (n =1756) 1.06 (0.93, 1.21) 0.39
NHS (n =1200) 1.15 (0.92, 1.43) 0.21
HPFS (n =1295) 0.98 (0.80, 1.21) 0.85
rs174627 (FADS2/FADS3)
Costa Rica Study (n =1756) 1.17 (0.95, 1.45) 0.14
NHS (n =1200) 0.92 (0.73, 1.15) 0.46
HPFS (n =1295) 0.97 (0.78, 1.20) 0.74
1All odds ratios were estimated using additive models. Models ﬁt to the Costa
Rican data were adjusted for age/sex/residence (by matching) and ancestry. Mod-
els ﬁt to the Nurses’ Health Study and the Health Professionals Follow-Up Study
data were adjusted for sex and age.
2Unadjusted for multiple testing.
MI in any of the three study populations. Given the evidence of
manifold physiological effects of PUFAs, is likely that the overall
effect of FADS polymorphisms on cardiovascular health is deter-
mined by a combination of mechanisms such as inﬂammation,
hyperlipidemia, endothelial function, cardiac rhythm, thrombosis,
and other pathways that were outside the scope of this investiga-
tion.Additionally, little is known about the putative cardiovascular
effects of the fatty acids in the side branches of the n−3 and
the n−6 pathways, i.e. ETA and EDA, which were signiﬁcantly
increased among carriers of the variant FADS genotypes in the
Costa Rica Study.
The strengths of our study include its large size, high response
rates, the representativeness of the sample of the Costa Rican
population, and extensive information on genetic and dietary
covariates that includedbiomarkermeasures. The observed associ-
ations between some of the SNPs and the adipose fatty acids in the
Costa Rica Study were robust and remained statistically signiﬁcant
even after applying the more conservative Bonferroni correction.
However, our ﬁndings should be interpreted in light of several
important limitations. First, the observational nature of the Costa
Rica Study, the NHS, and the HFPS precludes from establishing
any causal relations between the genetic and dietary exposures and
the outcomes. On a related note, the selected SNPs may merely be
in linkage disequilibrium with the true causal variant and not have
any physiologic effects of their own. Second, the fatty acid ﬁndings
were not replicated in independent populations due to current
unavailability of another large-scale cohort with adipose tissue
data; future such studies may consider conducting similar analyses
to establish the validity of our results. Third, the expression of fatty
acid concentrations as percentages instead of absolute measure-
ments, which is inherent to gas–liquid chromatography, implies
that the fatty acid outcomes are not independent and thus the
results need to be interpreted in the context of the entire pathway.
Fourth, adipose tissue concentrations of fatty acids are dependent
on a combination of genetic and environmental predictors includ-
ing but not limited to genetic variation in desaturases. Speciﬁcally,
we acknowledge that other relevant SNPs in the desaturase cluster,
particularly those that were identiﬁed subsequently to our geno-
typing efforts, may mediate the relationship between PUFA intake
and cardiovascular health. Finally, there were important differ-
ences in design between the discovery and the replication studies,
including but not limited to different matching criteria for cases
and controls.
In conclusion,we established associations between genetic vari-
ation in the desaturase cluster and adipose tissue fatty acids
in the Costa Rica Study, while demonstrating null associations
of the selected FADS variants with cardiovascular risk across
three cohorts. Future studies investigating mechanisms of PUFA
action will further our understanding of the biological inter-
play between genetic variation in desaturases and cardiovascular
health.
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